Gallen International Breast Cancer Conference proposed that Ki67 should be used to determine treatment in estrogen receptor-negative, HER2-negative T1-2N0-1 BC in accordance with the International Ki67 Breast Cancer Working Group. Here, MKI67 is linked to breast cancer.